CervoMed to Participate in Upcoming Investor Conferences
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in November 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Sidoti Virtual Micro Cap Conference on November 14 at 2:30 PM ET and the Stifel 2024 Healthcare Conference on November 19 at 3:00 PM ET. Both presentations will be available via webcast and accessible through CervoMed's website investor section.
Details
News Market Reaction – CRVO
The recorded move for CRVO in the trading session of this news was -2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November:
Sidoti Virtual Micro Cap Conference
Format: Corporate presentation
Date: Thursday, November 14, 2024
Time: 2:30 PM ET
Webcast Link: click here
Stifel 2024 Healthcare Conference
Format: Corporate presentation
Date: Tuesday, November 19, 2024
Time: 3:00 PM ET
Webcast Link: click here
The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.